Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Pujol

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerElizabeth Maunsell, Paul E Goss, Rowan T Chlebowski, et al.
Evolutionary Applications|April 26, 2021
Identifying key questions in the ecology and evolution of cancerAntoine M Dujon, Athena Aktipis, Catherine Alix-Panabières, et al.
Cancer Research|July 10, 2020
Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using <i>BRCA2</i> Exon 3 as a Model SystemHélène Tubeuf, Sandrine M Caputo, Teresa Sullivan, et al.
Frontiers in Oncology|November 16, 2018
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant CarriersFabienne Lesueur, Noura Mebirouk, Yue Jiao, et al.
European Journal of Human Genetics : EJHG|August 10, 2018
Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendationsPascal Pujol, Pierre Vande Perre, Laurence Faivre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
Cancers|April 14, 2025
Screening Mammography and Breast Cancer: Variation in Risk with Rare Deleterious or Predicted Deleterious Variants in DNA Repair GenesMaximiliano Ribeiro-Guerra, Marie-Gabrielle Dondon, Séverine Eon-Marchais, et al.
International Journal of Cancer|December 28, 2020
Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibilityChristine Lonjou, Séverine Eon-Marchais, Thérèse Truong, et al.
Breast Cancer Research : BCR|August 4, 2021
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutationMaximiliano Ribeiro Guerra, Juliette Coignard, Séverine Eon-Marchais, et al.
European Journal of Human Genetics : EJHG|April 16, 2015
Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer riskStéphanie Baert-Desurmont, Françoise Charbonnier, Estelle Houivet, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerElizabeth Maunsell, Paul E Goss, Rowan T Chlebowski, et al.
Evolutionary Applications|April 26, 2021
Identifying key questions in the ecology and evolution of cancerAntoine M Dujon, Athena Aktipis, Catherine Alix-Panabières, et al.
Cancer Research|July 10, 2020
Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using <i>BRCA2</i> Exon 3 as a Model SystemHélène Tubeuf, Sandrine M Caputo, Teresa Sullivan, et al.
Frontiers in Oncology|November 16, 2018
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant CarriersFabienne Lesueur, Noura Mebirouk, Yue Jiao, et al.
European Journal of Human Genetics : EJHG|August 10, 2018
Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendationsPascal Pujol, Pierre Vande Perre, Laurence Faivre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
Cancers|April 14, 2025
Screening Mammography and Breast Cancer: Variation in Risk with Rare Deleterious or Predicted Deleterious Variants in DNA Repair GenesMaximiliano Ribeiro-Guerra, Marie-Gabrielle Dondon, Séverine Eon-Marchais, et al.
International Journal of Cancer|December 28, 2020
Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibilityChristine Lonjou, Séverine Eon-Marchais, Thérèse Truong, et al.
Breast Cancer Research : BCR|August 4, 2021
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutationMaximiliano Ribeiro Guerra, Juliette Coignard, Séverine Eon-Marchais, et al.
European Journal of Human Genetics : EJHG|April 16, 2015
Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer riskStéphanie Baert-Desurmont, Françoise Charbonnier, Estelle Houivet, et al.
Pageof 10